Examples of using Gmts in English and their translations into Swedish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
-
Political
After booster, GMTs increased to.
The GMTs were, however, lower in women above 25 years.
In Protocol 007 peak anti-HPV 6, 11, 16, 18 GMTs were observed at Month 7.
Table 6: OPA GMTs in adults aged 18-49 years and 60-64 years given Prevenar 13a, b.
The sequential administration of Nimenrix one month after a DTaP-HBV-IPV/Hib vaccine resulted in lower GMTs for antibody against groups A, C and W-135.
The SPRs and GMTs are displayed in Table 13.
GMTs declined over time as expected
The SCRs and GMTs are displayed in Table 12.
GMTs were higher in girls
The booster dose led to a pronounced increase in GMTs and seroprotection rate remained at 100% two years after the booster.
The GMTs declined through Month 24 and then stabilized until at least Month 60.
anti-HPV 18 GMTs cLIA were observed at Month 7.
The GMTs appeared to be lower in the HIV infected group non overlapping 95% confidence interval.
proportions achieving hSBA≥1:8, and GMTs.
The GMTs were somewhat lower than reported in non-HIV infected subjects of the same age in other studies.
as measured by percentage of subjects with hSBA≥1:8 and GMTs.
In addition, OPA GMTs between subjects receiving Prevenar 13 with or without 2-PE were compared.
The administration of Nimenrix one month after the DTaP-HBV-IPV/Hib vaccine resulted in lower rSBA GMTs against groups A, C
After booster, GMTs increased to 16.7 µg/ ml
After the first dose, Prevenar 13 elicited antibody levels measured by both IgG GMCs and OPA GMTs that were statistically significantly higher when compared to levels prior to vaccination.
GMTs for HPV-6, -11, -16 and -18 were numerically comparable
Just before the booster injection anti-PRP GMTs were 0.40 µg/ ml and 0.64 µg/ ml for HEXAVAC and for the control group respectively.
To 99% of infants developed> 1.0 µg/ml of anti-PRP, a level associated with long- term protection against invasive Hib disease, and the GMTs ranged from 7.7 µg/ml to 14.0 µg/ml.
Rates of subjects with PRNT50≥1:10 and GMTs at Months 2, 6, 12, 24 and 36 are summarized in Table 3 for the ITT population.
The sequential administration of combined dTpa-IPV followed by Cervarix one month later tended to elicit lower anti-HPV-16 and anti-HPV-18 GMTs as compared to Cervarix alone.
The OPA GMTs were similar
One month after the booster dose increases of ELISA antibody GMCs and OPA GMTs were seen for each vaccine serotype
The rSBA GMTs were significantly lower in the subjects who had received a dose of ACWY-PS vaccine 30-42 months prior to Nimenrix(Table 14) see section 4.4.
greater than 0.15 µg/ ml; the GMTs were diminished compared to the control group 2.06 µg/ ml versus 3.69 µg/ ml.
Similar antibody GMCs and OPA GMTs were observed for all infants except a lower OPA GMT for serotype 5 in very preterm infants.